Abstract
Forty-six short children classified as familial short stature (FSS) or intrautcrinc growth retardation (1UGR) and normal GH reserve (≥ 10 ng/ml) were t recited with rhCH (Norditropin - Novo/Nordisk, 0.1 U/kg/d) for periods between 24-30 months. Their age ranged from 2.6 to 10 yrs (7 F, 39 M). The body measurements and hone age (BA) estimations were made by the same persons. The changes in SDS height registered were as follows:
In 17 children treatment was stopped mainly after 24 months treatment because of relative advancement of BA, and in 6 because of non-compliance. The remaining children advanced their BA parallel to the chronological age. The mean overall SDS height gain in all children over 30 months was 1 SDS, but 1UGR children gained more height than the FSS. It is concluded that, many young FSS and 1UGR children can benelit from long-term hGH treatment without seemingly preeluding their further height potential.
Article PDF
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Laron, Z., Lilos, P., Pertzelan, A. et al. LONG-TERM hGH TREATMENT OF SHORT PREPUBERTAL CHILDREN IMPROVES THEIR HEIGHT. Pediatr Res 33 (Suppl 5), S56 (1993). https://doi.org/10.1203/00006450-199305001-00316
Issue Date:
DOI: https://doi.org/10.1203/00006450-199305001-00316
- Springer Nature America, Inc.